Acquisition - June 11, 2013
AstraZeneca buys Pearl Therapeutics for $1.15 billion
On June 10, AstraZeneca announced the acquisition of California-based Pearl Therapeutics to strengthen the company’s respiratory portfolio. Pearl Therapeutics is a privately held company focused on the development of inhaled small-molecule therapeutics for respiratory disease. The acquisition will according to the press release give AstraZeneca access to a potential new treatment for chronic obstructive pulmonary […]
Acquisition - May 29, 2013
AstraZeneca acquires Omthera Pharmaceuticals
AstraZeneca has entered into a definitive agreement to acquire Omthera Pharmaeuticals for up to $443m. The specialty pharmaceutical company is based in Princeton, New Jersey, and focuses on the development and commercialization of new therapies for abnormal levels of lipids in the blood, referred to as dyslipidemia. The company’s investigational product, EpanovaTM, is aimed at […]
Biotech Business - April 29, 2013
MedImmune acquires AlphaCorePharma
AstraZeneca’s global biologics R&D arm MedImmune has acquired AlphaCorePharma. The Michigan-based biotech company focuses on the development of ACP-501, a recombinant human lecithin-cholesterol acyltransferase (LCAT) enzyme. Cardiovascular and metabolic disease is a core therapy area for AstraZeneca’s small and large molecule research. “As the science in this area continues to evolve, we are committed to […]
Drug Development Pharma - March 27, 2013
AstraZeneca keeps R&D in Mölndal
AstraZeneca’s site in Mölndal will continue to be a global center for research and development, the company recently announced. At the same time, another 2 300 employees are being made redundant. The company plans to invest in strategic R&D centers in the UK, the US and Mölndal, Sweden, focusing on small molecule and biologics R&D […]
Drug Development Pharma - February 27, 2013
Acturum takes over AstraZeneca facilities
AstraZeneca’s facility Snäckviken in Södertälje has been acquired by Acturum and will from now on be called BiovationPark Telge. The facility will host SP process development, Scania, Campus Telge and around 20 small research companies. Besides laboratories and offices, Acturum will install 5000 laboratory instruments at the facility. Astra will also hand over 15 drug […]
Drug Development Pharma - February 27, 2013
Orexo enters research agreement with AstraZeneca
The two companies have entered an agreement regarding a preclinical program for a potential novel treatment of respiratory diseases (OX-CLI). Orexo grants to AstraZeneca rights to conduct further preclinical research and evaluation of compounds in Orexo’s OX-CLI program. AstraZeneca also has an option to acquire the compounds pertaining to the program, subject to a full […]
